Tigecycline: A novel glycylcycline antiobiotic
August 1st 2005Highly resistant strains of both gram-positive and gram-negative bacteria are becoming commonplace in both the inpatient and outpatient setting. Recently developed antimicrobials have targeted resistant gram-positive pathogens, but the problem of resistant gram-negative pathogens remains. Tigecycline (Tygacil, Wyeth) is an injectable antimicrobial and the first in a new class of agents (the glycylcyclines) that possesses activity against key gram-positive and gram-negative bacterial pathogens. Tigecycline overcomes common tetracycline resistance mechanisms and has shown in vitro and in vivo activity against multidrug-resistant organisms. Tigecycline treatment produced clinical and microbiologic outcomes similar to standard comparator agents in patients with complicated skin and skin structure infections and complicated intra-abdominal infections and was approved for these indications in June 2005. The most common adverse events associated with tigecycline's administration during clinical trials were..
Read More
FDA approved moxifloxacin (Avelox, Schering-Plough) tablets and injection for the once-daily treatment of adults with complicated skin and skin structure infections (cSSSIs) caused by methicillin-susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae.
Read More
Bank on the fact that CDHC is here to stay
August 1st 2005As healthcare costs continue to spiral, the search for solutions is reaching a frantic pace. My experiences over the years have led me to believe that while Consumer- Directed Healthcare (CDHC) has entered the mainstream lexicon, it is far from understood.
Read More
As a third grader, Jean Fraser thought she would become a doctor. Her science class dissected a chicken, and she became so fixated by the experience that she described the process in detail to her father during the family dinner each night. Unbeknown to her until recently, her descriptions back then had made her father sick to his stomach.
Read More
NSAID utilization patterns following market withdrawal of rofecoxib
July 1st 2005Cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drugs (NSAIDs) have been widely prescribed for patients with arthritis and other conditions because of their lower risk for gastrointestinal adverse events compared with nonselective NSAIDs 1,2
Read More
Dapoxetine: A novel, fast-acting serotonin reuptake inhibitor
July 1st 2005Dapoxetine (Alza/Ortho-McNeil) is a novel oral medication undergoing FDA review for premature ejaculation, one of the most common disorders of sexual dysfunction in men. Dapoxetine is a fast-acting inhibitor of the serotonin reuptake transporter. It has a short half-life and is structurally related to the antidepressant fluoxetine, allowing for on-demand dosing.
Read More
Cost analysis of combination vs single dosage lipid-lowering
July 1st 2005A study was conducted to determine the cost and patient adher- ence rates of lipid-lowering therapy with an extended-release niacin and lovastatin (ERNL) combination agent versus a separate extended-release niacin and statin (ERN-S) combination or statin monotherapy.
Read More
Trends in utilization of alternative analgesics after rofecoxib withdrawal
July 1st 2005The objective of this study was to track the utilization of anti-inflammatory drugs among patients with active rofecoxib prescriptions at the time of market withdrawal through retrospective analysis of pharmacy records and to assess the need for COX-2 inhibitor therapy due to gastrointestinal risk factors.
Read More